Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2016 - 2023)

Myriad Genetics (MYGN) has disclosed Non-Current Deferred Tax Liability for 10 consecutive years, with $2.7 million as the latest value for Q3 2023.

  • Quarterly Non-Current Deferred Tax Liability fell 74.29% to $2.7 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Sep 2023, down 74.29% year-over-year, with the annual reading at $3.5 million for FY2022, 97.28% down from the prior year.
  • Non-Current Deferred Tax Liability for Q3 2023 was $2.7 million at Myriad Genetics, down from $3.7 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $174.3 million in Q4 2020, with the low at $2.7 million in Q3 2023.
  • Average Non-Current Deferred Tax Liability over 5 years is $52.7 million, with a median of $58.2 million recorded in 2021.
  • The sharpest move saw Non-Current Deferred Tax Liability soared 130.86% in 2020, then plummeted 97.28% in 2022.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $75.5 million in 2019, then skyrocketed by 130.86% to $174.3 million in 2020, then fell by 26.22% to $128.6 million in 2021, then tumbled by 97.28% to $3.5 million in 2022, then dropped by 22.86% to $2.7 million in 2023.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $2.7 million, $3.7 million, and $4.1 million for Q3 2023, Q2 2023, and Q1 2023 respectively.